Contrast agent developer Guerbet has received approval for a new indication for its Lipiodol Ultra Fluid ultrasound contrast agent in Denmark. Lipiodol is now approved in Denmark for use in conventional transarterial chemoembolization (cTACE) procedures.
Specifically, the approval covers the use of Lipiodol in adults with known intermediate-stage hepatocellular carcinoma, according to the company. Lipiodol acts as a contrast agent, a drug-eluting vehicle, and a dual arterioportal transient embolic for cTACE procedures.
